-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The alliance of 15 provinces including Jiangxi and Hebei Province will purchase 15 and 51 varieties respectively, involving oxacillin, ranitidine, tacrolimus, human growth hormone, etc
.
51 varieties began to report volumes, involving biological agents
51 varieties began to report volumes, involving biological agentsOn October 28, the Hebei Provincial Medical Insurance Bureau issued the announcement of the "Hebei Province Centralized Procurement Document for Chemicals and Biological Agents (HBYPJC-2022-01)", opening the centralized procurement of 51 drugs, including general chemical generic drugs (original research drugs, reference preparations, drugs that pass consistency evaluation, drugs deemed to pass consistency evaluation can voluntarily participate) and biological agents (see the end of the article for the full list).
This round of procurement cycle is two years, the agreed purchase volume of the first procurement year in the procurement cycle is filled in by the medical institution, the agreed purchase volume is in principle not less than 60% of the actual purchase volume of the same generic name and dosage form of drugs in each medical institution in the province within one year before the date of issuance of the procurement document, and the agreed purchase volume of the first year is announced on November 10, other processes can refer to the figure below
.
The price difference relationship of drugs involved in this centralized procurement is calculated according to the existing rules, according to the dosage form, specifications (the difference in loading volume is calculated according to the content difference price), and the packaging quantity, without considering the difference in packaging materials, and does not consider the differences
between large-volume injection, lyophilized powder injection, solvent crystalline powder injection and small-volume injection.
In terms of price, the price of the drug declared by the enterprise shall not be higher than the lowest hanging price (non-centralized procurement price) of the drug in the national provincial centralized procurement agency within one year before the date of issuance of this procurement document, and not higher than the lowest price selected by the national provincial, inter-provincial alliance and inter-provincial or provincial inland (municipal) level alliance centralized procurement of the drug (including the price that has not been executed).
Two "not higher" means that the company's quotation must not be higher than the lowest price in the country, and this requirement is likely to promote the enterprise to continue to reduce the price on the basis of the existing centralized procurement price to obtain the agreed purchase volume
.
At the same time, due to the requirements of "price linkage" in various provinces and cities, for example, Hebei mentioned that "if the selected enterprise produces new and lower centralized procurement prices in other regions, the enterprise should link the new selected price within 30 days", the "operation" space of drug prices will be compressed, and the overall drug price will be further reduced
.
In addition, measures such as key monitoring of the use of non-selected drugs by medical institutions will also urge medical institutions to give priority to the use of selected drugs and promote the implementation of
collective procurement.
Economic and technical standard and business standard 6:4, "one product and two choices"
Economic and technical standard and business standard 6:4, "one product and two choices"On October 28, the Jiangxi Provincial Pharmaceutical Procurement Service Platform issued the "Document on Centralized Procurement of Drugs in the Alliance of 15 Provinces (Autonomous Regions, Municipalities and Corps) (Draft for Comments)", which intends to purchase 15 non-evaluated varieties with quantity, and written feedback
can be provided before November 2.
The alliance consists of 15 provinces (autonomous regions, municipalities and XPCC), including Jiangxi, Inner Mongolia, Jilin, Heilongjiang, Zhejiang, Henan, Hunan, Guangxi, Hainan, Guizhou, Shaanxi, Qinghai, Ningxia, Xinjiang and the Xinjiang Production and Construction Corps.
The varieties to be included in the collection include 15 varieties such as oxacillin, vitamin D, pancreatic kininogenase, etc.
, and the procurement cycle is two years
in principle.
.
Unevaluated drugs refer to domestically produced generic drugs that have not passed the quality and efficacy consistency evaluation, and such drugs have not been included in the previous centralized procurement
of drugs organized by the state.
Due to the lack of "gold indicators" for quality and efficacy evaluation of such drugs, in order to avoid the problem of "bad money chasing good money" in quantitative procurement, Jiangxi Alliance adopted the "double envelope" comprehensive review and "one product and double selection" rule this time, and the comprehensive review score = economic and technical standard score × 60% + commercial standard score × 40%.
The products of the 1 company with the lowest quotation and the 1 company with the highest comprehensive evaluation score are to be selected; If the company with the lowest quotation and the highest overall score are the same company, only 1 company
will be selected.
The agreed purchase quantity of each variety in the first year shall be determined according to the following rules:
The agreed purchase quantity of each variety in the first year shall be determined according to the following rules:If an enterprise is selected, 50% of the base of the agreed procurement volume in the first year shall be the agreed procurement volume in the first year;
For the two selected enterprises, 75% of the agreed procurement volume base in the first year will be the agreed procurement volume in the first year, of which 50% will be used as the agreed procurement volume of the lowest price selected enterprise in the first year, and 25% will be used as the agreed purchase volume
of the highest scoring enterprise in the first year.
The economic and technical bids are evaluated based on the drug name and the combined dosage form of medical insurance, and the highest economic and technical standard score of the products of each reporting enterprise is evaluated
.
The economic and technical standards adopt a 100-point system, and the quality index, the supply security index and the comprehensive index account for 69 points, 13 points and 18 points
respectively.
Among them, the quality indicators include original research, evaluation, listing in Europe, the United States and Japan, and obtaining invention patents; The supply security index is assigned according to the distribution rate, the source of APIs, etc.
; The comprehensive indicators cover the national and procurement provinces of pharmaceutical prices, procurement credit evaluation, coverage of medical institutions, etc
.
Economic and technical standards are ranked from high to low according to the score, and the following figure ratio is shortlisted to enter the commercial standard and comprehensive evaluation
.
The business standard is full of 100 points, of which the quotation is reduced by 50 points and the absolute value of the quotation is 50 points, and the specific scoring method is as follows:
Attach:
Attach:
